|
1
|
Yamamoto S, Kawakami S, Yonese J, Fujii Y,
Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A and Fukui I:
Long-term oncological outcome and risk stratification in men with
high-risk prostate cancer treated with radical prostatectomy. Jpn J
Clin Oncol. 42:541–547. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Utomo NB, Mochtar CA and Umbas R: Primary
hormonal treatment in localized and locally advanced prostate
cancer: Effectiveness and survival predictive factors. Acta Med
Indones. 44:10–15. 2012.PubMed/NCBI
|
|
4
|
Gravdal K, Halvorsen OJ, Haukaas SA and
Akslen LA: A switch from E-cadherin to N-cadherin expression
indicates epithelial to mesenchymal transition and is of strong and
independent importance for the progress of prostate cancer. Clin
Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Theyer G, Schirmböck M, Thalhammer T,
Sherwood ER, Baumgartner G and Hamilton G: Role of the
MDR-1-encoded multiple drug resistance phenotype in prostate cancer
cell lines. J Urol. 150:1544–1547. 1993.PubMed/NCBI
|
|
6
|
Linja MJ, Savinainen KJ, Saramäki OR,
Tammela TL, Vessella RL and Visakorpi T: Amplification and
overexpression of androgen receptor gene in hormone-refractory
prostate cancer. Cancer Res. 61:3550–3555. 2001.PubMed/NCBI
|
|
7
|
Mackillop WJ, Ciampi A, Till JE and Buick
RN: A stem cell model of human tumor growth: Implications for tumor
cell clonogenic assays. J Natl Cancer Inst. 70:9–16.
1983.PubMed/NCBI
|
|
8
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of
CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schratt GM, Tuebing F, Nigh EA, Kane CG,
Sabatini ME, Kiebler M and Greenberg ME: A brain-specific microRNA
regulates dendritic spine development. Nature. 439:283–289. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehler MF and Mattick JS: Non-coding RNAs
in the nervous system. J Physiol. 575:333–341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amankwah EK, Anegbe E, Park H, Pow-Sang J,
Hakam A and Park JY: miR-21, miR-221 and miR-222 expression and
prostate cancer recurrence among obese and non-obese cases. Asian J
Androl. 15:226–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rane JK, Scaravilli M, Ylipää A, Pellacani
D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T and
Maitland NJ: MicroRNA expression profile of primary prostate cancer
stem cells as a source of biomarkers and therapeutic targets. Eur
Urol. 67:7–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lessard L, Bégin LR, Gleave ME, Mes-Masson
AM and Saad F: Nuclear localisation of nuclear factor-kappaB
transcription factors in prostate cancer: An immunohistochemical
study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagler C, Zänker KS and Dittmar T: Cell
fusion, drug resistance and recurrence CSCs. Adv Exp Med Biol.
714:173–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tu SM and Lin SH: Prostate cancer stem
cells. Clin Genitourin Cancer. 10:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Z, Filho MS and Nör JE: The biology
of head and neck cancer stem cells. Oral Oncol. 48:1–9. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J,
Yang Q, Xu Y and Li F: Aberrant expression of microRNAs in gastric
cancer and biological significance of miR-574-3p. Int
Immunopharmacol. 13:468–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Nohata N, Yamasaki T, Gotanda T,
Tachiwada T, et al: Novel oncogenic function of mesoderm
development candidate 1 and its regulation by miR-574-3p in bladder
cancer cell lines. Int J Oncol. 40:951–959. 2012.PubMed/NCBI
|
|
27
|
Chekulaeva M and Filipowicz W: Mechanisms
of miRNA-mediated post-transcriptional regulation in animal cells.
Curr Opin Cell Biol. 21:452–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tricoli JV, Schoenfeldt M and Conley BA:
Detection of prostate cancer and predicting progression: Current
and future diagnostic markers. Clin Cancer Res. 10:3943–3953. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ross JS, Kallakury BV, Sheehan CE, Fisher
HA, Kaufman RP Jr, Kaur P, Gray K and Stringer B: Expression of
nuclear factor-kappa B and I kappa B alpha proteins in prostatic
adenocarcinomas: Correlation of nuclear factor-kappa B
immunoreactivity with disease recurrence. Clin Cancer Res.
10:2466–2472. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ismail HA, Lessard L, Mes-Masson AM and
Saad F: Expression of NF-kappaB in prostate cancer lymph node
metastases. Prostate. 58:308–313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gilmore TD and Gerondakis S: The c-Rel
transcription factor in development and disease. Genes Cancer.
2:695–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clark JM, Aleksiyadis K, Martin A, McNamee
K, Tharmalingam T, Williams RO, Mémet S and Cope AP: Inhibitor of
kappa B epsilon (IκBε) is a non-redundant regulator of
c-Rel-dependent gene expression in murine T and B cells. PLoS One.
6:e245042011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alves BN, Tsui R, Almaden J, Shokhirev MN,
Davis-Turak J, Fujimoto J, Birnbaum H, Ponomarenko J and Hoffmann
A: IκBε is a key regulator of B cell expansion by providing
negative feedback on cRel and RelA in a stimulus-specific manner. J
Immunol. 192:3121–3132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Refaat A, Zhou Y, Suzuki S, Takasaki I,
Koizumi K, Yamaoka S, Tabuchi Y, Saiki I and Sakurai H: Distinct
roles of transforming growth factor-beta-activated kinase 1
(TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in
human T cell lymphotropic virus 1-transformed T helper 17 cells
producing interleukin-9. J Biol Chem. 286:21092–21099. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thome M, Charton JE, Pelzer C and
Hailfinger S: Antigen receptor signaling to NF-kappaB via CARMA1,
BCL10, and MALT1. Cold Spring Harb Perspect Biol. 2:a0030042010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fontan L, Yang C, Kabaleeswaran V, Volpon
L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R,
Yang SN, et al: MALT1 small molecule inhibitors specifically
suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 22:812–824.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
O'Connor S, Shumway SD, Amanna IJ, Hayes
CE and Miyamoto S: Regulation of constitutive p50/c-Rel activity
via proteasome inhibitor-resistant IkappaBalpha degradation in B
cells. Mol Cell Biol. 24:4895–4908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Q and Verma IM: NF-kappaB regulation in
the immune system. Nat Rev Immunol. 2:725–734. 2002. View Article : Google Scholar : PubMed/NCBI
|
